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Summary Angiogenesis is the formation of new blood vessels from the existing vasculature. Vascular endothelial growth factor (VEGF) is an
endothelium-specific angiogenic factor strongly implicated in pathological angiogenesis. In this study, the mRNA and protein expression of the
four alternatively spliced VEGF isoforms (121, 165, 189 and 206 amino acids) were examined in normal and malignant breast tissues. Three
VEGF transcripts were detected in both (121>165>189), whereas only VEGF165 protein was detected. The tumours expressed more VEGF
mRNA (P = 0.02) and protein (P < 0.0001), with eight-fold more VEGF protein generated per mRNA unit (P = 0.009). To examine this further,
the expression of elF-4E, a translation initiation factor, was examined. Increased elF-4E mRNA levels were detected in the tumours
(P < 0.0001) that correlated with VEGF mRNA (P = 0.0002), implying co-regulation of these genes. VEGF mRNA expression was elevated
in tumours expressing the epidermal growth factor receptor (P < 0.01), but there was no difference according to oestrogen receptor status
(P = 0.9), node status (P = 0.09) or between differing histologies (P = 0.4). These data suggest that elevated VEGF protein expression, by
both enhanced transcription and translation, is a potential means by which tumour angiogenesis is induced in breast carcinomas. VEGF
expression is also significantly associated with factors correlating with a poor outcome, implying a role in progression of this disease.
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Angiogenesis is the formation of new blood vessels from the
existing vasculature. It is a complex process involving degradation
of the basement membrane, endothelial proliferation, migration,
tube formation and the initiation of blood flow. Angiogenesis
occurs in a wide range of biological events, including the female
reproductive cycle, embryonic development and wound healing
(Folkman and Shing, 1992). In the pathological setting, it is an
important component of many diseases including rheumatoid
arthritis and diabetic retinopathy, and is a critical, although not the
only, step necessary for the growth and metastasis of tumours
(Folkman, 1990). Under physiological conditions, angiogenesis is
regulated strictly by a balance of stimulation and inhibition, but in
the neoplastic state there appears to be a loss of control (Liotta et
al, 1991).
Although several types of angiogenic factors, including lipids
and peptides, have been identified (reviewed Folkman and
Klagsbrun, 1987; Bicknell and Harris, 1991; Bouck, 1993; Scott
and Harris, 1994), the focus has remained on the polypeptide
growth factors. Of these, the angiogenic growth factor most
strongly implicated in tumour angiogenesis is vascular endothelial
growth factor (VEGF).
In addition to being the most selective endothelial mitogen
known (Leung et al, 1989), VEGF elicits other effects on endothe-
lial cells, including chemotaxis (Kock et al, 1994), increased
permeability (Keck et al, 1989) and the release ofproteinases such
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as urokinase plasminogen activator and collagenase (Pepper et al,
1992; Unemori et al, 1992).
VEGF expression has been identified at the mRNA or protein
level in a range ofmalignancies, including gastrointestinal (Brown
et al, 1993a; Hsu et al, 1995; Shiraishi et al, 1995; Takahaski et al,
1995; Warren et al, 1995; Maeda et al, 1996), renal (Brown et al,
1993b; Sato et al, 1994; Takahaski et al, 1994), bladder (Brown et
al, 1993b), lung (Mattern et al, 1995), ovarian (Boocock et al,
1995; Olson et al, 1995), endometrial (Harrison-Woolrych et al,
1995), cervical (Guidi et al, 1995) and hepatocellular carcinomas
(Mise et al, 1996) In human breast carcinoma, VEGF mRNA
expression has been reported to be higher in tumour cells
compared with normal ductal cells using in situ hybridization
(Brown et al, 1995). The levels of VEGF protein have been quan-
titated in this malignancy and found to correlate with increased
microvessel density (Toi et al, 1994; 1996) and early relapse in
primary breast carcinoma (Toi et al, 1994). A recent study has
demonstrated that VEGF protein levels in tumour samples are
significantly higher in tumours compared with matched normal
samples (Yoshiji et al, 1996).
To date, all studies of VEGF in breast carcinoma and normal
tissues have examined total mRNA and protein. There are,
however, four isoforms with significantly different biochemical
and biological effects that are generated by alternative splicing
(Houck et al, 1991; Tischer et al, 1991). The smallest isoform,
VEGF121, is freely soluble and does not bind heparin. The inclu-
sion of more cationic exons in the next two isoforms, VEGF165
and VEGF189, confers heparin-binding properties (Tischer et al,
1991; Ferrara et al, 1992) resulting in binding to the extracellular
matrix after secretion (Houck et al, 1992; Park et al, 1993). This
heparin-binding fragment has been shown recently to confer an
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increased mitogenic potency on the VEGF165 compared with the
VEGF121 isoform (Keyt et al, 1996), although there are no reports
on the relative potency of the VEGF189 isoform. The largest
isoform, VEGF206, has only been identified in a fetal liver library
and has similar properties to VEGF189 (Houck et al, 1991), but
little is known about its biological relevance.
VEGF expression is regulated by a number of factors including
hypoxia and hypoglycaemia in glioblastoma spheroids (Shweiki et
al, 1995), and hormones in tissues from the female reproductive
tract (Cullinanbove and Koos, 1993). Hypoxia, a feature ofall solid
tumours, is the most potent stimulus, and its induction results from
a combination of increased transcription and mRNA stability.
Recently, however, a post-transcriptional mechanism for VEGF
regulation has been identified, acting through the enhancement of
recruitment and binding ofthe mRNA to the ribosome. The mRNA
of growth factors such as VEGF characteristically have long 5'
untranslated regions (UTRs) with complex secondary structures
that render them inefficiently translated (Kevil et al, 1996). eIF-4E
is a polypeptide that binds the 7-methylguanosine-containing cap of
mRNA, unwinds the 5' UTR of the target mRNA facilitating the
identification of the translation start site by the ribosome. Elevated
eIF-4E levels have been associated with increased growth rates and
transformation of cell lines (De Benedetti and Rhoads, 1990), and
increased levels of VEGF protein (Kevil et al, 1996). Increased
expression of eIF-4E has been found in both breast carcinoma
tissues compared with fibroadenomas (Kerekatte et al, 1995) and
breast carcinoma cell lines compared with normal breast cell lines
(Anthony et al, 1996) and may represent a means of regulating
expression of genes including angiogenic factors and subsequent
tumour growth (Kevil et al, 1996).
The aims of this study were to quantify and locate the expres-
sion ofthe VEGF isoforms at the mRNA and protein levels in both
normal and breast carcinoma tissues. I'he relationship between
mRNA and protein expression was studied in tumours vs normal
tissues as well as the potential role of eIF-4E in breast carcinoma
in regulating that expression. The levels of VEGF mRNA, protein
and eIF-4E were also compared with factors known to affect prog-
nosis such as oestrogen receptor (ER), epidermal growth factor
receptor (EGFR), node status and histology of the tumours.
MATERIALS AND METHODS
Isolation of RNA from cells and tissues and
ribonuclease protection assay (RPA)
Total RNA was prepared by acid guanidinium thiocyanate-
phenol-chloroform extraction (Chomczynski and Sacchi, 1987).
For the ribonuclease protection assays, radiolabelled riboprobes
were synthesized with [Qc-32P]CTP (Amersham, UK) from
linearized plasmid DNA using the in vitro transcription method
(Ausubel et al 1987).
Two VEGF riboprobes were used: the first was designed to
protect the full length of the smallest isoform (VEGF121 yielding
a 471-base band, with a lower band of 427 representing the
remaining isoforms). This 520-base probe was generated by
linearizing the full-length cDNA for VEGF121 (including 26 bp of
3' untranslated sequence) cloned into pBluescript SK with EcoRV
and transcribing with T7 RNA polymerase. To determine the
isoforms contributing to this second smaller band, a new construct
was designed to protect its largest fragment, VEGF,89, with the
remaining isoforms forming two bands lower on the gel. The
cDNA coding for the mature VEGF189 protein was cloned into
BS KS + in the XbaI and EcoRI sites and the probe generated
using NotI and T3 polymerase. The largest protected fragment was
567 bases, with a 345-bp fragment formed from both the
VEGF121 and the VEGF165 isoforms, and a third band of 150
bases representing VEGF165 alone. The generation of the eIF-4E
riboprobe has been described elsewhere (De Benedetti et al, 1991).
RPAs were performed essentially as described (Ausubel et al,
1987) with a minimum of 10- c.p.m. of each antisense riboprobe
hybridized overnight at 55°C to each sample with 10 ltg of transfer
RNA as a negative control. The RNAase digestion of the unhy-
bridized RNA fragments was performed the next day by adding
350,l of RNAase digestion buffer with 40,g ml' RNAase A and
1000 units ml' RNAase T1 to each sample and incubating for
30 min at room temperature. The RNAases were inactivated by
adding 12.5 gl ofa mixture containing 16% sodium dodecylsulphate
(SDS) solution with 4 tg gl-' proteinase K and incubating at 37°C
for 15 min. After phenol extraction and precipitation in 2 volumes of
ethanol, the samples were resuspended and loaded onto a 6% poly-
acrylamide/urea sequencing gel followed by autoradiography.
The resulting bands were quantitated densitometrically
(Bioimage densitometer, Millipore) and signals normalized to the
external control. This control was formed from the hybridization
of a sense and antisense riboprobe to glyceraldehyde-3-phosphate
(GAPDH), with the sense riboprobe generated by linearizing the
construct 30 bases beyond the end of the GAPDH sequence. This
gives two protected fragments: the endogenous gene (120 bp) and
the external control fragment (150 bp). Before aliquotting, each
sample was run on a 1% agarose gel under RNAase-free condi-
tions, and the RNA concentration measured spectrophotometri-
cally, as described in Scott et al (1997).
In situ hybridization
In situ hybridizations were performed using single-stranded RNA
35S-labelled riboprobes hybridized with4-jtm sections offormalin-
fixed, paraffin-embedded tissue prepared earlier by dewaxing in
xylene/0.1% DEPC then rehydrating in serial washes of 100%,
80%, 60% and 30% ethanol. The sections were then permeabilized
with proteinase K (20 gg ml') for 10 min, washed thoroughly in
phosphate buffered saline (PBS) and the tissues acetylated with 0.1
M triethanolamine and acetic anhydride (1.25 ml in 500 ml) before
dehydration in ethanol in the reverse order mentioned above, ready
for hybridization. The sections were then incubated with 106
c.p.m. ofriboprobe in hybridization buffer (Senior et al, 1987) that
had been heated to 80°C, and incubated overnight at 55°C. After
washing extensively in 50% formamide at 50°C, the sections were
incubated with 100 tg ml' RNAase A for 1 h to remove the unhy-
bridized riboprobe. The slides were then washed, fixed in 30%
ethanol/0.3 M ammonium acetate, air dried and placed in emulsion
(Senior et al, 1987). After 7 days, the slides were developed,
washed and the signal visualized, and compared with Giemsa-
counterstained light-field sections. A f-actin hybridization was
used as a positive control.
Extraction and analysis of tumour membranes and
cytosols
Tumour membranes, cytosols and nuclei were prepared as
described previously (Sacks et al, 1993). Briefly, the tumours were
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frozen in liquid nitrogen, ground up in a similar way as for RNA
extraction before addition of an ice-cold Hepes/EDTA buffer
containing proteinase inhibitors, then homogenized using a Dounce
homogenizer. The homogenate was centrifuged in a bench-top
centrifuge at 4°C, yielding the first fraction containing mostly DNA
and other nuclear debris, and was retained as the 'nuclei' fraction.
The supernatant was removed carefully and centrifuged at
100 000g to bring down any membrane fractions (the 'membrane'
fraction while the supernatant forms the 'cytosol' fraction).
ELISA analysis of tissues
The VEGF protein levels were measured using ELISA (R&D
Systems, Abingdon, UK). As this ELISA had not been used previ-
ously for assaying such samples, the accuracy was validated by
comparing the VEGF protein standards diluted 50:50 with the
sample buffer (Tris-buffered saline pH 7.5) with that provided by
the manufacturer, as well as the effects of adding a constant
amount of sample to the standards made up with the manufac-
turer's buffer. A final validation was carried out by serially
diluting a sample to determine whether the detection of VEGF
decreased accordingly. The study was commenced after
confirming the accuracy ofthe ELISA under these conditions.
Table 1 The clinicopathological characteristics of the patients whose breast
carcinomas were examined for VEGF expression
Patient characteristics Number
Age mean (median, range) years 55 (35-86)
<50 years 18
>50 years 34
Lymph nodes
Positive/negative 15/37
Histology
Ductal 41
Lobular 7
Other 4
ERa (median, range) (1.6-742)
<10 15
>10 37
EGFRa (median, range) 13 (0-77)
<20 32
>20 20
afmol mg-1 protein.
Table 2 The numbers of cases examined and levels of VEGF mRNA and
protein expression in normal and breast carcinoma tissues. The VEGF
mRNA was standardized against an external control, whereas the VEGF
protein was measured as pg per 100 ,ug total protein for each sample
VEGF mRNA VEGF protein
(standardized to external (pg per 100 ,ug total
control) protein)
Sample Normal Tumour Normal Tumour
Number 16 46 15 38
Mean + s.e.m. 8.9 +2.3 18.6 +2.6 21.9 ± 4.1 277 +68
Median 5.9 12.8 19 113
Min-max 0.7-37 1.2-8 2.8-49 6-2305
Immunoblotting analysis of tissues
The protein samples were separated by sodium dodecyl sulphate
polyacrylamide gel electrophoresis (SDS-PAGE) and transferred
onto a PVDF membrane at 4°C at 15 V overnight. The membrane
was then blocked for a minimum of 2 h in blocking buffer (PBS,
0.1I% Tween 20, 5% Marvel fat-free milk) before incubation with
the anti-VEGF rabbit polyclonal antibodies (Zhang et al, 1995)
diluted 1:200 in blocking buffer. After washing, the membrane
was incubated for 30 min with ['251]protein A (Amersham, UK),
washed and then exposed directly to radiographic film at -800C.
Statistics
All descriptive and non-parametric statistics were performed using
Statview 4.5 (Abacus Concepts, Berkeley, CA, USA). The
comparative statistical analysis was calculated using the
Mann-Whitney U-test, whereas the correlations were calculated
using the Spearman rank correlation. The mean values are
presented with the standard error of the mean.
RESULTS
VEGF mRNA expression in human breast carcinoma
and normal tissues
Fifty-two cases ofbreast carcinoma were examined for expression
of either VEGF mRNA and/or protein (see Table I for clinico-
pathological details). VEGF mRNA expression was examined in
46 cases, together with matched samples of normal breast tissues
resected during mastectomy from 11 ofthose 46 cases, one case of
unmatched normal tissues and four samples ofnormal tissues from
breast reduction specimens (Table 2). All tumour and normal
samples expressed the isoforms in order ofdecreasing abundance,
121>165>189, except for one tumour in which the pattern of
expression of VEGF was 165>121>189. Although the VEGF 121
isoform was the most abundant species in most cases, there was
considerable variation in the extent to which it predominated,
ranging from 41% to 83% ofthe total VEGF message. In addition,
a band of approximately 280 bases was detected in 36 cases of
breast carcinoma but not in any ofthe normal breast tissues.
When measuring the levels of VEGF mRNA, initially GAPDH
levels were considered as an internal control. However, levels of
this enzyme fluctuated sixfold when compared with an external
spiked control; when both VEGF mRNA and GAPDH mRNA
expression was standardized against an external spiked control,
there was a significant correlation between their expression levels
(r = 0.77, P < 0.0001, Spearman rank coefficient test). Thus,
thereafter, an external spiked control was used to standardize the
densitometric signals between samples.
The levels ofVEGF mRNA, standardized to an external control,
varied up to 70-fold across the tumours (n = 46, mean 18.6 ± 2.6),
20-fold across the normal tissues resected from mastectomy speci-
mens (n = 12, mean 9 ± 3) and two-fold across the normal tissues
from mammoplasty tissues (n = 4, mean 8.5 ± 1.7) (Table 2). There
was a significant difference between the levels ofVEGF mRNA in
the tumour compared with all the normal samples (P = 0.02).
There was also a significant difference when the reduction
mammoplasty samples were excluded, that is only the normal
tissues taken from regions adjacent to the tumours were included
in the analysis (P = 0.03). When the levels of VEGF mRNA in
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Figure 1 An RNAase protection demonstrating increased expression of
both elF-4E and VEGF mRNA in the tumour samples from three cases with
matching normal samples, as well as low levels of expression in four normal
samples taken from reduction mammoplasties. The control used was formed
from the hybridization of sense and antisense GAPDH riboprobes added to
each sample
normal breast and carcinoma tissues taken from the same patient
were compared, the VEGF mRNA expression was higher in 9 out of
11 cases (n = 11; normal mean = 9 + 3.3; tumour mean = 15.6 + 5,
P = 0.09), but this was not significant, probably reflecting the
smaller numbers available for direct comparison (see Figure 1).
The VEGF mRNA expression in EGFR-positive tumours
(n = 17; mean 28.6 ± 5.8) was significantly higher than the EGFR-
negative cases (n = 29; mean = 13.2 ± 2.3; P < 0.01). There was no
significant difference between VEGF mRNA expression in cases
negative or positive for ER status (P = 0.09), node status (P = 0.9)
or between differing histologies (P = 0.4; n = 39 ductal, five
lobular and two other histology subtypes).
The distribution of VEGF mRNA in breast carcinoma
To determine which cells were expressing the VEGF mRNA,
formalin-fixed, paraffin-embedded samples of tumour and
A
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normal breast were analysed by in situ hybridization. The
linearized VEGF121 template was used to generate riboprobes for
this experiment.
The highest levels ofVEGF mRNA were detected in the epithe-
lial cells in both normal and malignant tissues (Figure 2), with the
latter expressing higher levels than their normal counterparts. Low
levels of VEGF mRNA were detected in the stromal cells of both
tumour and normal tissues.
VEGF protein expression in human breast carcinoma
and normal tissues
The protein levels in the tumours and normal tissue, the latter all
from mastectomy specimens, were examinedusing ELISA (R & D
Systems, UK). Having validated the ELISA for use with these
samples (see Materials and methods), the subcellular localization
of VEGF in samples from the membrane, cytosolic and nuclear
fractions of eight tumours and six normal samples taken from
mastectomy specimens were examined. In all of the tumour
samples examined using ELISA, the highest VEGF concentration
(pg per 100 l g total protein) was found in the membrane fraction
(see Table 3), followed by the cytosolic fraction with lower levels
in the nuclear fraction. The membrane VEGF concentration (mean
873 ± 261) was significantly higher than the nuclear fraction
(mean 367 ± 165) in the tumour samples (n = 8, P = 0.04) but not
the cytosolic fraction (mean 503 ± 156; P = 0.2). In the normal
samples, the VEGF concentration highest in the membrane frac-
tion (mean 35.5 ± 5.4), which was significantly higher than the
cytosol fraction (cytosol mean 17.2 ± 2.7; n = 6; P = 0.02) but not
the nuclear fraction (n = 6, mean 22.7 ± 3.6; P = 0.07). Thus, the
membrane fraction was used to measure the levels of VEGF
protein in a further 33 tumour and 13 normal samples. In 13
normal samples, the corresponding tumour tissues from the same
patient were available for comparison.
n
Figure 2 In situ hybridization with light (A and C) and dark (B and D) fields demonstrating VEGF expression predominantly in the epithelial component of both
normal (A and B) and breast carcinoma tissues (C and D)
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Table 3 The subcellular localization of VEGF protein in normal and
malignant breast tissues
VEGF protein (pg per 100gg total)
Tissue fraction Normal (n = 6) Tumour (n = 8)
Membrane 35.5 + 5.4 873 ± 261
Cytosolic 17.2 + 2.7 503 + 156
Nuclear 22.7 ± 3.6 367 ± 165
Table 4 The amount of protein generated per unit of mRNA in normal and
breast carcinoma tissues
pg protein per unit mRNA
Sample Normal Tumour
Number 13 13
Mean±s.e.m. 17.9 + 3.2 144 ± 17.9
Median 16.8 80
Min-max 5.6-32.5 14.6-395
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Figure 4 The correlation of VEGF mRNA and protein in the breast
carcinoma cases (r= 0.6, P < 0.0007). After measurement by densitometry,
the mRNA was standardized against an external control, whereas the protein
is expressed as pg VEGF per 100 gg total protein for each sample
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0 1 I I I I I samples (lanes 3-7) by immunoblotting using a rabbit polyclonal antibody to
VEGF. The characteristic doublet seen under reducing conditions (due to
1 2 3 4 5 6 7 8 9 10 unequal glycosylation) is the same size as the VEGF165 control (lane 2) and
larger than the VEGF121 protein from conditioned media of transfected cells
Figure 3 The amount of VEGF (pg per 100lug total protein) generated per (lane 1), with the molecular weight marker sizes indicated at the left. An
unit RNA in normal vs tumour samples taken from the same patients. D, pg aliquot (100gg) of total protein was loaded for each tumour sample for
VEGF unit RNA normal; *, pg VEGF unit RNA tumour comparison with 1,g of recombinant VEGF165
The VEGF protein expression in the normal samples (n = 15,
mean 21.9 i 4.1) differed significantly from that in the tumour
samples (n = 38, mean 277 + 68, P < 0.0001) (see Table 2).
Furthermore, there was up to sixfold (mean 3.6 ± 0.6) more
protein generated per unit mRNA in the 13 matched tumours
(mean protein concentration 161 ± 40) compared with the corre-
sponding normal samples (mean protein concentration 15.8 ± 2.8,
P < 0.0001) (see Table 4 and Figure 3).
There was a strong correlation between the tumour VEGF
mRNA and protein levels (n = 38, mRNA mean 18.6 ± 2.6, protein
mean 277 ± 68, r = 0.6, P < 0.0007) (Figure 4). There was no
significant difference in VEGFprotein expression in cases positive
or negative for EGFR (P = 0.62), ER expression (P = 0.3), node
involvement (P = 0.56) orbetween differing histologies (P = 0.37).
VEGF isoform expression in normal and breast
carcinoma samples
VEGF165 was the only isoform detected in nine carcinoma and
two normal samples using immunoblotting. As with the ELISA,
the expression was detected predominantly in the membrane frac-
tion, with some also detected in the cytosolic fraction of samples
expressing high levels of VEGF overall. The VEGF protein is
detected as a doublet under reducing conditions because ofdiffer-
ential glycosylation (Ferrara et al, 1992) (Figure 5) and was the
same size as the recombinant VEGF165 doublet. Although
detectable in the membrane fractions of xenografts formed from
MCF-7 cells transfected with VEGF121, neither this isoform nor
VEGF189 was detected in the human breast carcinoma samples.
The expression of elF-4E in normal and breast
carcinoma tissues
eIF-4E mRNA levels were measured in three normal samples from
mastectomy cases, four reduction mammoplasty samples and 44
breast carcinoma cases and standardized against the spiked
external control. eIF-4E mRNA expression was detected in two
reduction mammoplasty samples, with low levels in the normal
tissues from mastectomies. In the three paired normal and tumour
samples, the levels of eIF-4E mRNA were between four and
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Figure 6 The correlation between elF-4E and VEGF mRNA expression in
the 38 tumours examined for both factors (r= 0.58, P= 0.0002). Each was
measured by densitometry and standardized against a spiked external
control
42-fold higher in the tumours. When the levels of all of the
normal tissues (n = 7, normal mean 0.5 ± 0.22, median 0.1) were
compared with the tumour tissues examined (n = 42, tumour
mean 6.8 ± 0.8, median 4.8), there was a significant difference
(P <0.0001).
In the cases in which both tumour eIF-4E mRNA (mean
6.8 ± 0.8) and VEGF mRNA expression (mean 19.3 ± 2.7) were
examined there was a strong correlation (n = 42, r = 0.58,
P = 0.0002) (see Figure 6), but not between eIF-4E mRNA and
VEGF protein expression (r = 0.07, P = 0.98).
DISCUSSION
VEGF mRNA and protein levels correlate with increased
microvascular density and a poor prognosis in breast carcinoma
(Toi et al, 1994). High vascular counts in breast tumours as an
index ofangiogenesis are associated with a significant reduction in
survival (Horak et al, 1992; Weidner et al, 1992; Fox et al, 1994),
and thus it is likely that VEGF is partially responsible for breast
cancer angiogenesis.
The findings in this study of VEGF mRNA and protein in all
samples analysed are in contrast with one report (Toi et al, 1995)
and in agreement with another (Yoshiji et al, 1996). The latter
study reported higher VEGF mRNA in 18 breast carcinomas
compared with normal breast tissues from the same patients, and
detected VEGF immunohistochemically only in the tumour
sections. In this study, the mRNA levels in 46 cases and 16 normal
samples (11 matched normal tissues, one unmatched and four
breast reduction samples) were quantitated using ribonuclease
protection assays. The protein levels in 38 cases were measured
using ELISA and compared with 13 matched normal samples and
two unmatched normal tissues from mastectomies. In addition to
there being significant differences between the VEGF expression
by tumours and the normal samples at both the mRNA and the
protein levels, there was a strong correlation between the mRNA
and protein expression. Furthermore, although there was a correla-
tion between mRNA and protein expression, the amount ofprotein
detected in normal tissues was several fold lower than in the
tumours for a given level of mRNA. This suggests that VEGF
expression is modified post-transcriptionally in tumours compared
with normal breast tissue.
There are several possible explanations for this difference.
Elevated levels of eIF-4E protein had been reported in breast
carcinoma cell lines (Anthony and De Benedetti, 1996), and in one
previous report in which the expression in 38 breast carcinomas
was compared with fibroadenomas or breast reduction specimens
(Kerekatte et al, 1995). The same number of tumours was exam-
ined in this study, but, in addition, the eIF-4E expression in
tumours was compared with normal tissues from the same patient,
as well as samples from breast reductions. The eIF-4E mRNA
levels were up to 40-fold higher in the tumour samples compared
with the paired normal samples. Consistent with the findings of
others examining similar samples for eIF-4E protein expression
(Kerekatte et al, 1995), the eIF-4E mRNA levels in reduction
mammoplasty samples were very low in two samples and unde-
tectable in two samples. In agreement with the previous report,
there was no correlation with ER status (Kerekatte et al, 1995), nor
with EGFR, node status, nor histology.
There was a strong correlation between tumour VEGF mRNA
and eIF-4E mRNA levels. As eIF-4E does not regulate VEGF
mRNA transcription, this suggests that a common factor regulates
both eIF-4E and VEGF mRNA expression resulting in a marked
elevation of VEGF protein levels. eIF-4E expression is regulated
in response to growth induction by c-myc (Rosenwald et al, 1993)
and eIF-4E phosphorylation is regulated by overexpression of
ornithine decarboxylase (Shimogori et al, 1996) that is, in turn,
regulated when eIF-4E is overexpressed (Shantz et al, 1996).
Recent data have shown that mutant p53 protein regulates VEGF
mRNA expression (Kieser et al, 1994), suggesting a link with
tumour progression, and it would be of interest to investigate
whether mutant p53 protein also regulates eIF-4E.
There was no correlation between VEGF protein and eIF-4E
mRNA levels in the tumours examined. Although eIF-4E protein
is reported to correlate with the mRNA levels (Rosenwald et al,
1993; Anthony and De Benedetti, 1996), the eIF-4E protein has a
short half-life compared with the mRNA, is subject to phosphoryl-
ation, and therefore the percentage of functional translation initia-
tion factor protein may differ between tumour samples. It is also
possible that eIF-4E represents just one mechanism regulating
post-transcriptional VEGF expression in malignancy. Other mech-
anisms include stabilization of the VEGF protein, as when bound
to ctI-macroglobulin (Soker et al, 1993).
The VEGF mRNA levels were significantly higher in EGFR-posi-
tive tumours. EGF stimulation ofEGFR has been reported to induce
VEGF expression in glioblastomas, thereby inducing angiogenesis
and resulting in their characteristic vascular appearance (Goldman et
al, 1993), and a similarmechanism may operate in these breast carci-
nomas. EGFR expression (Nicholson et al, 1988) and increased
microvascular density have both been associated with a poor prog-
nosis in breast cancer patients (Fox et al, 1994). The elevated VEGF
is likely to contribute to the increased vessel density, and the associ-
ation with a poorer prognosis implicates VEGF further as a major
angiogenic factor contributing to tumour growth and metastasis.
When measuring the VEGF protein, the highest levels were found
in the membrane fraction, with lower levels in the cytosols. VEGF
was detected in the nuclear fraction, which may reflect minor conta-
mination of this fraction during preparation and/or translocation of
VEGF into the nucleus (Moroianu 1994). It is less likely to represent
artefact as there was a wide variation in expression in the nuclear
fractions prepared from different tumours, with no relationship to
total cellular VEGF protein levels. Only VEGF165 was detectable
using immunoblotting, despite detection of VEGF121, VEGF165
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and VEGF189 transcripts. The VEGFI21 protein may be difficult to
detect because it is freely soluble and may bind and be internalized
soon after secretion; its detection in the VEGF121 transfectant
xenografts, however, confirmed that it can be detected ifsufficiently
abundant. It is possible, therefore, that antagonists such as suramin
could be used to block the angiogenesis induced by the heparin-
binding VEGF165 isoform (Braddock et al, 1994).
The extent to which the VEGF121 mRNA isoform predominated
varied from 41% to 83%, with VEGF165 making up most of the
remaining VEGF signal. VEGF189 was detected in all the samples
but at a much lower level. In addition to the recognized isoforms,
an additional band was detected that may correspond to another
splice variant. This was most likely to be the 267-bp fragment
described in glioblastomas (Berkman et al, 1993) as it was also
detected in the glioblastoma cell line used as a loading control.
In determining the levels of mRNA, several internal and
external controls to ensure even loading were assessed. These
included the glycolytic enzyme, GAPDH, as an internal control,
and the combination of GAPDH sense and antisense probes as an
external control. The latter proved to be better as it is not possible
to rely upon a gene used as an internal control being expressed
equally in all of the samples. In this study, when standardized
against an external control, there was a sixfold fluctuation in the
levels of the commonly used housekeeping gene, GAPDH, and
also a strong significant correlation between GAPDH and VEGF
mRNA levels. This may be explained by a factor such as hypoxia,
which is present in all solid tumours and which is known to up-
regulate expression of both genes (Shweiki et al, 1992; Graven
et al, 1994). GAPDH is also up-regulated during proliferation
(Meyer et al, 1992; Mansur et al, 1993), which may explain the
elevated levels in some tumours and the lower expression in
normal tissues. The co-existence of increased VEGF and GAPDH
mRNA expression may indicate a more metabolically active
tissue. Given the correlation between VEGF mRNA levels and a
poorer prognosis in breast carcinoma (Relf et al, 1997), an
independent comparison ofGAPDH and prognosis is warranted.
In summary, significantly elevated levels of VEGF mRNA and
protein have been demonstrated in this study in breast carcinomas
compared with normal tissues. The cells responsible for this
enhanced VEGF expression are the tumour cells, with lower levels
of expression by the stromal elements. The VEGF mRNA levels
were higher in EGFR-positive cases and correlated with eIF-4E and
GAPDH mRNA expression. There was a strong correlation between
VEGF mRNA and protein expression. This suggests that VEGF
expression in breast carcinoma is controlled by a combination of
transcriptional regulation by factors such as hypoxia and EGF, and
translational regulation by factors such as eIF-4E. Each factor may
itselfbe subject to regulation: eIF-4E mRNA levels are regulated by
hypoxia (unpublished observation), whereas the activity of the
protein is modulated by phosphorylation (Rhoads, 1993).
The greatest difference between tumour and normal breast
tissues were amounts of VEGF protein expressed by each. This
emphasizes the potential importance of factors such as eIF-4E in
tumorigenesis in a common cancer. The role of this transcription
initiation factor in malignancy is beginning to emerge, and mecha-
nisms that regulate its expression may be of therapeutic interest.
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